Bright Minds Biosciences, Inc. (DRUG)
50.75
-1.25
(-2.40%)
USD |
NASDAQ |
Oct 08, 12:37
Bright Minds Biosciences Debt to Equity Ratio : 0.0002 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0002 |
| March 31, 2026 | 0.0003 |
| December 31, 2025 | 0.0012 |
| September 30, 2025 | 0.0015 |
| June 30, 2025 | 0.0027 |
| March 31, 2025 | 0.003 |
| December 31, 2024 | 0.0032 |
| September 30, 2024 | 0.0215 |
| June 30, 2024 | 0.0023 |
| March 31, 2024 | 0.0061 |
| December 31, 2023 | 0.009 |
| September 30, 2023 | 0.0111 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0118 |
| March 31, 2023 | 0.0121 |
| December 31, 2022 | 0.0114 |
| September 30, 2022 | 0.0133 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Amgen, Inc. | 4.903 |
| Lineage Cell Therapeutics, Inc. | 0.0377 |
| Recursion Pharmaceuticals, Inc. | 0.0728 |
| Agenus, Inc. | -1.458 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 218.74M |
| Total Liabilities (Quarterly) | 1.793M |
| Shareholders Equity (Quarterly) | 216.95M |
| Current Ratio | 121.98 |
| Net Debt Paydown Yield | 0.00% |